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Edited by Beat ImhofAbstract Hyperproliferation of the premalignant epithelium is
critical for colonic carcinogenesis; however the mechanisms re-
main largely unexplored. We report herein that prior to occur-
rence of neoplastic lesions in the azoxymethane-rat model of
colon carcinogenesis; the tumor suppressor gene C-terminal
Src kinase (Csk) was down-regulated with a concomitant in-
crease in Src activity. Furthermore, pharmacological or genetic
(RNA interference) inhibition of Csk resulted in increased prolif-
eration in colon cancer cell lines through the mitogen-activated
protein kinase dependent pathway. Thus, we demonstrate, for
the ﬁrst time, that Csk suppression is an important early event
in colorectal cancer pathogenesis.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Despite medical advances, colorectal cancer (CRC) remains
the second leading cause of cancer deaths in the United
States [1]. Understanding the molecular events in colon carci-
nogenesis is of paramount importance in designing eﬀective
screening and chemopreventive strategies. One of the hall-
marks of early colon carcinogenesis is diﬀuse increase in co-
lonic epithelial proliferation. This hyperproliferation not
only allows genetically initiated clones to expand, but serves
as a valuable intermediate biomarker in colon cancer preven-
tion studies [2–4]. While numerous downstream events haveAbbreviations: CRC, colorectal cancer; Csk, C-terminal Src kinase;
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doi:10.1016/j.febslet.2005.05.030been demonstrated (e.g., activation of mitogen-activated pro-
tein kinase (MAP) kinase signaling), the upstream molecular
determinants of the hyperproliferative colonic ﬁeld has been
largely unexplored.
Src is a proto-oncogene that links extracellular cues to prolif-
erative signaling cascades. Activation of this non-receptor tyro-
sine kinase has been implicated in the development of a variety
of malignancies including 80% of colon cancers [5–8]. Src has
been demonstrated to govern a myriad of pro-neoplastic eﬀects,
including, increased cell proliferation, decreased apoptosis, in-
creased invasiveness and increased angiogenesis and, therefore,
has been associated with a worse prognosis [7]. The mechanism
of Src activation in CRC is multifactorial, but down-regulation
of its inhibitor, C-terminal Src kinase (Csk) appears to be ofma-
jor importance. Csk acts as a tumor suppressor gene by render-
ing an inhibitory phosphorylation to Src on tyrosine 527 [9,10].
Indeed, in most CRCs there is a reciprocal relationship between
Csk and Src. Moreover, overexpression of Csk mitigates the
neoplastic phenotype of CRC cells [11–14].
Thus, while the importance of Src in established CRC is
unequivocal, there is minimal data during the early, premalig-
nant phases with its characteristic diﬀuse increase in colonic
epithelial proliferation. Src has been demonstrated to impact
upon a number of signaling pathways important in the early
hyperproliferation of colon carcinogenesis (e.g., MAP kinase
cascade); however no previous studies have explored the role
of Csk/Src axis at this stage. In order to address this issue,
we assessed Csk/Src levels in the premalignant mucosa of the
azoxymethane (AOM)-treated rat, a robust, well-validated
model of experimental colon carcinogenesis. Furthermore, to
demonstrate that Csk suppression is causative of cellular
hyperproliferation, we examined the eﬀect of both pharmaco-
logical and RNAi-mediated Csk-inhibition on cell growth in
the human CRC cells. Finally, we determined that the growth
promoting eﬀects of Csk-down-regulation are largely mediated
through the MAP kinase pathway.2. Materials and methods
2.1. Animals
All animal studies were performed in accordance with the Institu-
tional Animal Care and Use Committee of Evanston Northwestern
Healthcare. Male Fischer 344 rats (150–200 g) were randomized to
two groups receiving either 2 weekly intraperitoneal injections of eitherblished by Elsevier B.V. All rights reserved.
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trol). Rats were euthanized 8 weeks post-second injection of AOM/sal-
ine after injecting 50 mg/kg of 5 0bromo 2 0deoxyuridine (BrDu) two
hours before euthanization (to detect proliferation). Colons were re-
moved and divided into proximal and distal segments. Mucosal scrap-
ings from the distal segment were subjected to RT-PCR analysis.
Immunohistochemistry was used to detect levels of Csk, total Src,
tyrosine phosphorylated Src (amino acids 527 and 416) and BrDu
incorporation.2.2. Immunohistochemistry
Immunohistochemistry was performed as previously reported [15].
Brieﬂy, 5 lm sections were deparaﬃnized, underwent heat-based anti-
gen retrieval and were probed with Csk (BD Transduction Labs, Lex-
ington, KY), total Src (Santa Cruz Biotechnology, Santa Cruz, CA)
Src-527 and Src-416 (Cell Signaling, Beverly, MA). Slides were devel-
oped with a Vectastain ABC kit (Vector Laboratories, Burlingame,
CA). BrDu incorporation was detected by using a BrDu staining
kit (Zymed Laboratories Inc., CA). Slides were scored on a 4 point
scale by a gastrointestinal pathologist (J.H.) blinded to treatment
group.2.3. Csk inhibitor
The Csk-inhibitor ASN 2324598 was selected from ASINEX library
of compounds based on the initial in silico screening. Activity and
speciﬁcity of the Csk-inhibitor was conﬁrmed in vitro using human re-
combinant Csk kinase by ELISA-based inhibition assay [16].
2.4. Cell culture
HT-29 and HCT-116 cells (American Type Tissue Culture, Rock-
ville, MD) were grown as previously described [17]. To assess the eﬀect
of Csk-loss on HT-29 cells, the cells were treated with either vehicle or
Csk inhibitor ASN 2324598 (20 lM) for 24 h. To demonstrate the Csk-
modulation of the MAP kinase pathway, HT-29 cells, were pre-treated
with MEK1/2 inhibitor U0126 (20 lM) (Calbiochem, San Diego, CA)
for 1 h and then treated with ASN 2324598 (20 lM) for 48 h. The pro-
teins were subjected to Western blot analysis.
2.5. Cell proliferation assay
HT-29 cells were treated either with the Csk-inhibitor ASN 2324598
(5–20 lM)or vehicle for 24 h. Cell numberwas assessed bymeasurement
of the cleavage of the tetrazolium salt WST-1 (4-[3-(4-iodophenyl)-2-
(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) to formazan
according to the manufacturers instructions (Roche Diagnostics India-
napolis, IN). Brieﬂy, cells were grown in 96 well plates in a ﬁnal volume
of 100 ll and then incubated with 10 ll of WST-1 reagent for 30 min at
37 C in a humidiﬁed 5% CO2 incubator. Conversion of the tetrazolium
salt to formazan was measured at absorbance of 440 nm on Spectramax
Plus spectrophotometer (Molecular Devices, Sunnyvale, CA).2.6. Src activity assay
Equal amounts of HT-29 lysates (750 lg protein) underwent immu-
noprecipitation with a Src-speciﬁc antibody (Santa Cruz Biotechnol-
ogy) for overnight at 4 C. Following washing, Src was eluted from
beads and underwent tyrosine kinase assay using a kit as per manufac-
turers instruction (Chemicon International, Temecula, CA).2.7. siRNA transfection
In order to study whether Csk inhibition at mRNA level brings
about cellular hyperproliferation, we knocked down Csk gene expres-
sion in human CRC cell line HCT-116 by using Csk TranSilent Short
hairpin-loop RNA (shRNA) vector (Panomics, Redwood City, CA)
and monitored the downstream eﬀects. The Csk-shRNA vector and
the empty control vector were transfected in HCT-116 cells by using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to manufac-
turers instructions. After transfection, cells were incubated at 37 C in
a humidiﬁed 5% CO2 incubator for 72 h. Total RNA and protein was
isolated from the cells using TRI reagent (Sigma, St. Louis, MO) and
subjected to RT-PCR and Western blotting analyses, respectively, by
standard methods.2.8. RT-PCR
Total RNA was extracted using TRI Reagent (Sigma). After DNase
treatment, ﬁrst-strand cDNA synthesis and PCR ampliﬁcation for
Csk, Src and proliferating cell nuclear antigen (PCNA) were carried
out using the Invitrogen RT-PCR kit following the manufacturers
protocol. RT-PCRs were normalized to cyclophilin.
2.9. Western blot analysis
Immunoblot analysis was performed using standard techniques as
previously described [15]. Brieﬂy, 25 lg protein was separated via
SDS–PAGE, transferred to polyvinylidene ﬂuoride membranes and
probed with antibodies speciﬁc for Src-Tyr-527, Src-Tyr-416, MAP ki-
nase kinase, p-Raf-ser 338 (Cell Signaling, Beverly, MA) and pERK,
PCNA, Ki-67, CSK and Cyclin D1 (Santa Cruz Biotechnology, Santa
Cruz, CA) overnight at 4 C. Xerograms were developed with enhanced
chemiluminescence (Amersham-Pharmacia, Piscataway, NJ) and quan-
titated with a densitometer. Consistency in protein loading was assessed
by probing membranes with b-actin (Sigma, St Louis, MO).3. Results
3.1. Expression of Csk and Src in preneoplastic colonic mucosa
We ﬁrst analyzed protein expressions of Csk and Src in pre-
malignant colonic mucosa of AOM-treated rats by immunohis-
tochemistry. Csk was dramatically suppressed (55% of control,
P = 0.017) in the AOM rats with a concomitant decline (58% of
control, P = 0.04) in Src 527 levels and increase in Src 416 indi-
cating that Src was activated (Figs. 1A and B). Furthermore, the
AOM rats showed a marked increase in cell proliferation as
manifested by greater BrDu incorporation (Figs. 1A and B).
We further demonstrated that the Csk down-regulation oc-
curred at the transcriptional level, with a marked decrease in
CskmRNA (30% reduction, P < 0.01). However, no alterations
in Src message or protein (Figs. 1A and 2) was noted. Thus, Csk
was down-regulated in preneoplastic colonic mucosa which led
to corresponding activation of Src.
3.2. Eﬀect of Csk-inhibitor ASN 2324598 on CRC cells
To determine the biological signiﬁcance of Csk inhibition in
colon cancer cells, we obtained highly speciﬁc pharmacological
Csk-inhibitor ASN 2324598 from ASINEX (Moscow, Russia).
The inhibitor caused a concentration-dependent increase in
cell number in HT-29 cells (150–300% of the control,
P < 0.05) as assessed by cell proliferation assay (Fig. 3B).
The IC50 of ASN 2324598 for CSK was 1.2 lM with 10 lM
suppressing 99% activity. The speciﬁcity of ASN 2324598 is
supported by the observation that in the 10 lM ASN
2324598 had minimal suppression of activity of ﬁbroblast
growth factor receptor, glycogen synthase kinase 3b, Aurora
A (rest activity 100 ± 2.4%, 93 ± 3.3% and 100 ± 0.8%, respec-
tively, data not shown).
As demonstrated in Fig. 4B, pharmacological inhibition of
Csk resulted in decreased in Src-527 (74% of vehicle,
P = 0.03) and a concomitant increase in Src-416 (182% of vehi-
cle, P = 0.035). In order to conﬁrm Src activation, we per-
formed an immunoprecipitation-kinase assay showing a 52%
increase in Src activity (P = 0.03) (Fig. 4A). The downstream
consequences of Src induction included activation (as deter-
mined by phospho-speciﬁc antibody) of Raf (ser338) (160%
of vehicle, P < 0.05), MAP kinase kinase (MEK) (155% of
vehicle, P < 0.01), MAP kinase (127% of vehicle, P < 0.05),
PCNA (233% of vehicle, P = 0.03) and Cyclin D1 (137% of
vehicle, P < 0.05) (Fig. 4B). Thus, inhibition of Csk activity
Fig. 1. (A) Csk, Src, Src-527, Src-416 and BrDu incorporation in
preneoplastic colonic mucosa in AOM-rat model of colon carcino-
genesis. Colonic tissue sections of male Fischer 344 rats treated with
either saline or azoxymethane were subjected to immunohistochemical
analysis as described in Section 2. AOM treatment resulted in CSK
suppression with a corresponding decrease in Src-527. While total Src
was unchanged, Src-416 (activated) was increased with an increase in
proliferation (BrDu). Representative slides are shown in the ﬁgure.
n = 10. (B) Scoring of immunohistochemistry. At 8 weeks post AOM
injection, there was a signiﬁcant decrease in CSK and Src-527 with a
concomitant increase in BrDu (marker of proliferation). \ P < 0.05.
Fig. 2. Levels of Csk and Src message in preneoplastic colonic
mucosa. Total RNA from the mucosal scrapings of distal colons of
control and AOM rats was subjected to RT-PCR using standard
techniques.
Fig. 3. (A) CSK/Src in human colon cancer cell lines: Immunoblot
analysis demonstrating CSK and Src expression in both HT-29 and
HCT-116 cells. (B) Eﬀect of Csk inhibition on cell proliferation. The
Csk inhibitor ASN 2324598 (at the concentration of 5–20 lM) caused
signiﬁcant increase in HT-29 cells as assessed by WST-1 cell prolif-
eration assay. \P < 0.05, \\P < 0.01 versus time-matched vehicle-
treated cells.
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vation and ultimately resulted in increased cell proliferation.
3.3. Eﬀect of MEK1/2 inhibition on the activity of Csk inhibitor
ASN 2324598
Thus, our above data implicates MAP kinase activation in
the pro-proliferative eﬀects of Csk inhibition. In order to dem-onstrate causation, we used a selective MEK inhibitor U0126
(20 lM). Pre-treatment of HT-29 cells with U0126 completely
abrogated the pro-proliferative eﬀects of ASN 2324598, pro-
viding compelling evidence that increased cell proliferation
by Csk-inhibition is mediated through the MAP kinase path-
way (Fig. 4C).
Fig. 4. (A) CSK inhibition increases Src activity. HT-29 cells were
treated with the Csk inhibitor ASN 2324598 (20 lM) for 24 h and Src
activity was measured through an immunoprecipitation-kinase assay
as detailed in Section 2. (B) Eﬀect of Csk inhibition on cell signaling
cascade in CRC cell lines. HT-29 cells were treated with the Csk
inhibitor ASN 2324598 (20 lM) for 24 h and the proteins were
subjected to Western blotting by standard techniques. (C) Eﬀect of
MEK1/2 inhibitor on the activity of ASN 2324598. HT-29 cells were
treated with the Csk inhibitor ASN 2324598 in the presence of MEK1/
2 inhibitor U0126 (20 lM, 1 h pre-treatment) for 48 h. Proteins were
subjected to Western blotting and probed for PCNA to determine cell
proliferation.
Fig. 5. Knockdown of Csk gene expression by RNAi. Csk-speciﬁc
TranSilent shRNA vector and the empty control vector (Panomics,
CA) was transfected into CRC cell line HCT-116 and the cells were
incubated for 72 h. (A) Demonstrates message alterations using RT-
PCR whereas (B) assesses proteins using Western blot analysis.
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While the speciﬁcity of ASN 2324598 has been well-vali-
dated, we wanted to conﬁrm the results using a genetic
(RNA interference) approach. We assessed the eﬀect of Csk-
speciﬁc shRNA vector on CRC cell line that showed robustly
expressed CSK and Src levels (Fig. 3A). Introduction of
shRNA vector resulted in a 54% decrease (P < 0.01) in Csk
mRNA level and 38% reduction in CSK protein (P < 0.01)as compared to the vector control (Fig. 5). There was a corre-
sponding 46% decrease (P < 0.01) in Src-527 and a 63% in-
crease (P < 0.05) in Src-416, indicating Src activation. Csk
gene knockdown caused marked increase in cell proliferation
as measured by increase in PCNA message (168% of control,
P < 0.05), PCNA protein (170% of control, P = 0.03) and
Ki-67 (177% of vehicle, P = 0.048) protein. This further sub-
stantiated that Csk knockdown leads to increased cellular pro-
liferation in human CRC cells.4. Discussion
We demonstrate herein, for the ﬁrst time, that the Csk-Src
axis is dysregulated at the premalignant phase of colon carci-
nogenesis and these changes are correlated with the colonic
hyperproliferation. While genetic lesions (e.g., increased Wnt
signaling through adenomatous polyposis coli truncations)
are well-established in neoplastic lesions [18] and found focally
in the uninvolved mucosa (K-ras mutations in aberrant crypt
foci), no diﬀuse mutational events have been noted in the pre-
malignant ﬁeld that could be responsible for ubiquitous nature
of mucosal hyperproliferation. The AOM-treated rat repre-
sents an excellent model to study the premalignant alterations
owing to its close resemblance to the morphological, genetic
and cellular events in human colon carcinogenesis and the
well-deﬁned chronology of lesions [19]. Speciﬁcally, adenomas
develop at about 20 weeks post carcinogen whereas carcino-
mas require 35–40 weeks. Indeed, there are similar increases
in proliferative indices in the 8-week-old AOM-treated rat
and the endoscopically normal mucosa of patients harboring
adenomas. Thus the 8 week time point of the AOM-treated
rat should correlate well with the uninvolved colonic mucosa
of patients at risk for developing neoplasia.
Although previous studies have shown that Src is activated
as early as the adenomatous polyp stage, ours is the ﬁrst to
Fig. 6. Proposed mechanism for Csk-mediated colonic hyperproliferation.
D.P. Kunte et al. / FEBS Letters 579 (2005) 3497–3502 3501document this at the histologically normal mucosa where the
lesions are initiated. Several mechanisms have been proposed
for Src activation in colon cancers including activating muta-
tions (seen in 12% of CRC) [20], transcriptional overexpression
and downregulation of the tumor suppressor gene, Csk (most
common mechanism). Cam and colleagues [11] noted a strong
correlation between Csk loss and Src activation (r2 = 0.71;
P < 0.0001). While we did not evaluate other mechanisms,
our observation that Csk down-regulation was associated with
a corresponding decrease Src-527 supports this notion. Fur-
thermore, total Src mRNA and proteins levels were unchanged
arguing against overexpression.
In order to support causality of Csk/Src modulation and
premalignant hyperproliferation, we were unable to use animal
models since Csk knockouts are embryonically lethal [21] and
there have been no studies on the dosage/pharmacokinetics of
the Csk inhibitors that would indicate an eﬃcacious regimen to
suppress colonic epithelial Csk activity. We, therefore, studied
the in vitro eﬀect of Csk inhibition on human CRC cell lines.
We demonstrate that the highly speciﬁc pharmacological
Csk-inhibitor (ASN 2324598) caused marked increase in cell
number with a concomitant increase in PCNA. Furthermore,
duplication of these results with a genetic (RNAi) approach
conﬁrmed the speciﬁcity of these ﬁndings.
We further explored the mechanisms through which Csk/
Src axis transduces the pro-proliferative signals. We demon-
strate that not only did pharmacological suppression of Csk
trigger activation of the Raf/MEK/MAP kinase cascade,
but importantly, this pro-proliferative response was abro-
gated by the MEK inhibition. These data provide a link be-
tween the Csk-Src axis and MAP kinase signaling cascade
(Fig. 6) which is known to be critical in human and experi-
mental colon carcinogenesis. Indeed, targeting the MAP ki-
nase pathway has been shown to dramatically reduce
tumorigenesis in experimental models of colon carcinogenesis
[22]. While the Csk-Src eﬀects on proliferation and the MAP
kinase cascade appear paramount for increasing the cellular
growth, there are a myriad of other pro-neoplastic eﬀects of
Src that may be mediated through diﬀerent molecular eﬀec-
tors. For instance, the increased invasiveness may be medi-
ated through E-cadherin [23] or integrin pathways, eﬀecting
the downstream AP-1 and or lymphocyte enhancing factor(LEF) transcriptional regulators. The angiogenic eﬀect may
be mediated through vascular endothelial growth factor
(VEGF) [24]. Thus, modulating the Csk tumor suppressor
gene may impact on numerous facets of colon carcinogenesis
in both the initiation and progression phases.5. Conclusion
This report is ﬁrst to demonstrate that the Csk/Src axis dys-
regulation is involved in the early, premalignant stages of co-
lon carcinogenesis. Loss of the tumor suppressor gene Csk
fosters the hyperproliferative ‘‘ﬁeld’’ that is characteristic of
human and animal colon carcinogenesis. Thus, augmenting
Csk may represent a novel means of preventing CRC. Further-
more, assaying the Csk/Src axis may also be useful as a bio-
marker for colon carcinogenesis. Future studies are needed
to fully elucidate the role of Csk/Src in early colonic neoplastic
transformation.Acknowledgments: We thank Alexander V. Kolesnikov, Institute of
Bioorganic Chemistry, Moscow, Russia for cloning and puriﬁcation
of the Csk protein. We also thank Yuri A. Fedotov of ASINEX for
his help in screening and activity assay of the Csk inhibitor.References
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